Akeso stock closed at HK$95.35 after a flat week on the screen, yet the latest half year numbers tell a more charged story. Revenue for H1 2026 reached C¥1,805.68m while the company still reported a net loss of C¥424.22m. The market is now trying to decide whether this report justifies paying a rich P/S multiple that sits well above the Hong Kong biotech pack, or whether sentiment has run ahead of the balance between growth hopes and ongoing losses.
Love the revenue scale Akeso is reaching but concerned about ongoing losses and a rich P/S multiple? Check out 612 high quality undiscovered gems for companies that pair strong fundamentals with more balanced profitability profiles.
H1 2026 Earnings Summary
- Revenue (H1 2026 vs H1 2025): C¥1,805.68m vs. C¥1,411.54m (higher revenue in the latest half)
- Net Loss (H1 2026 vs H1 2025): C¥424.22m loss vs. C¥570.08m loss (smaller loss in the latest half)
- Basic EPS (H1 2026 vs H1 2025): C¥0.4618 loss per share vs. C¥0.6368 loss per share (smaller loss per share in the latest half)
- Trailing 12 month Net Loss (H1 2026 TTM vs H1 2025 TTM): C¥967.16m loss vs. C¥1,113.03m loss (smaller trailing loss over the most recent 12 months)
Tired of scrolling through dense earnings tables and raw figures for Akeso? Get the full picture of the stock in a clean visual dashboard that highlights its valuation in context through the company report for Akeso.
Akeso’s Bull Case Hinges On Clinical Wins Converting To Cash
Bulls argue Akeso is building a high quality oncology and immunology franchise that can eventually support scale and better margins. The latest half year numbers partly support that view. Revenue reached C¥1,805.68m and the trailing 12 month loss narrowed to C¥967.16m. That points to growing commercial activity even while the company still reports sizeable losses.
The more important test for the bullish narrative is pipeline execution. Here Akeso is clearly hitting milestones. Ivonescimab has a first Phase III win against global standard of care in biliary tract cancer and is already approved with chemotherapy in first line advanced squamous NSCLC, where it is described as a new standard. Gumokimab is approved for psoriasis and a supplemental NDA is filed. Multiple antibody drug conjugate programs have moved into Phase I and II. These events align with expectations for a broader, later stage portfolio that can support future revenue diversification.
Compare Akeso’s clinical momentum with market expectations and see whether analysts think this operational progress supports the current HK$95.35 share price by checking the consensus price target analysis for Akeso.Akeso Bear Case: Profit Strain And Execution Overhang
Bears argue Akeso is locked into a model of heavy spending, pressured pricing and thin margins. The latest half year keeps that concern alive. Revenue is C¥1,805.68m, yet Akeso still reports a C¥424.22m net loss and a trailing 12 month loss of C¥967.16m. That is progress, but it does not yet show a clear path to self funding.
The clinical news flow is strong, including Phase III wins for ivonescimab and new approvals for gumokimab, yet there is no disclosure here that these wins are translating into visibly stronger profitability. Bears who worry that guideline and reimbursement gains come with steep price cuts do not see that fear disproved. Funding risk also stays on the table. The scale of ongoing losses means Akeso still needs either firmer margins or external capital at some point, which is exactly where the bearish narrative is focused.
With Akeso still unprofitable and carrying C¥967.16m in trailing losses, it is fair to ask how long the current cash position can support this spend rate without fresh equity or debt. Check the full solvency, liquidity and cash runway breakdown in the financial health analysis of Akeso stock.Stay Ahead With Simply Wall St
If Akeso’s growing revenue base and ongoing losses have caught your attention, register for free with Simply Wall St and add it to your Watchlist to track the share price against fair value and watch for an entry point that fits your plan. After you invest, keep a clear view of Akeso and your other holdings with the Portfolio Command Center that highlights the most important updates without the noise. For the longer term, tap into thousands of investor insights and discussions through the Community to see how others are thinking about similar risks and opportunities. By spotting potential catalysts and warning signs early, you give yourself a better chance of staying ahead of the market.
Seeking Alternatives Beyond Akeso Stock
Akeso may be front of mind today, yet fresh ideas are constantly gaining breakout momentum under the radar for now. Scan these curated shortlists before the window drops and act now.
- Spot early strength in cash generative compounders by reviewing the list of solid balance sheet and fundamentals stocks (427 results) while the market’s attention is still caught elsewhere and get in early.
- Ride potential income momentum with hand picked high yield opportunities by checking the 416 dividend fortresses before others chase payouts that might already be flying.
- Channel your curiosity into future facing themes by assessing the 38 power grid technology and infrastructure stocks while these infrastructure plays are still under the radar for now.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com